Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/22/18 → 6/1/19 |
Funding
- Covance Inc. (Prot #BAY 1436032/19036 // Prot #BAY 1436032/19036)
- Bayer HealthCare Pharmaceuticals, Inc. (Prot #BAY 1436032/19036 // Prot #BAY 1436032/19036)
Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok
- Altman, Jessica K (PD/PI)
Project: Research project